|[October 22, 2013]
The Rosen Law Firm Announces Investigation of Securities Fraud Claims Against Osiris Therapeutics, Inc. -- OSIR
NEW YORK --(Business Wire)--
The Rosen Law Firm, P.A. announces that it is investigating potential
securities claims against Osiris Therapeutics, Inc. (NASDAQ:OSIR)
resulting from allegations that the Company may have issued materially
false statements to investors about the development and progress of its
On October 21, 2013, shares fell $2.98 or by 17.01%, closing at $14.51.
This occurred after the Company revealed that the Food and Drug
Administration ("FDA") classified OSIR's wound care product, Grafix, as
a drug thereby requiring additional regulatory measures. On September
26, 2013, OSIR received an untitled letter from the FDA raising
compliance and regulatory issues with several of the Company's products.
In their pres release on October 21, 2013, OSIR stated that it reached
an agreement with the FDA on September 30, 2013. Part of that agreement
includes that OSIR will have to file a Biologics License Application in
order to obtain the drug's approval from the FDA.
The Rosen Law Firm is investigating a securities class action lawsuit on
behalf of OSIR investors. If you have any information to aid the
investigation or if you purchased or acquired OSIR stock and would like
to recover your losses, please visit the website at http://rosenlegal.com
for more information. You may also contact Laurence Rosen, Esq., or
Phillip Kim, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via
e-mail at email@example.com
The Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and shareholder
Attorney Advertising. Prior results do not guarantee a similar outcome.
[ Back To Technology News's Homepage ]